---
title: "Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293203327.md"
description: "Veraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the biology and non-clinical development plan for its lead BiTAC-TCE program. The regulatory feedback supported the platform rationale, offering early de-risking and clearer guidance on safety assessments and pharmacokinetics strategy."
datetime: "2026-07-20T11:01:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293203327.md)
  - [en](https://longbridge.com/en/news/293203327.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293203327.md)
generator: "portal-rs"
---

# Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan

-   Veraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biology and non-clinical development plan for its lead BiTAC-TCE program. \* Regulatory feedback supported the platform rationale, providing early de-risking and clearer guidance on safety assessments and pharmacokinetics strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200700OMX\_\_\_\_\_CNEWS\_EN\_GNW1001213475\_en) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [Veraxa Biotech files Form 3 for Interim CFO Carl von Halem](https://longbridge.com/en/news/296530272.md)
- [Veraxa Biotech shareholders approved all proposals at extraordinary general meeting](https://longbridge.com/en/news/293793007.md)
- [Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027](https://longbridge.com/en/news/296546698.md)
- [PharmAla Biotech says USPTO grants US patent for enantioselective MDMA, MBDB processes](https://longbridge.com/en/news/296608164.md)
- [Active Biotech wins European regulatory approval to resume tasquinimod myelofibrosis trial enrollment](https://longbridge.com/en/news/296500289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**